Antisense oligodeoxynucleotides against thrombomodulin suppress the cell growth of lung adenocarcinoma cell line A549

Thrombomodulin (TM), an anticoagulant factor on endothelial cells, is known to be expressed in non-endothelial cells as well. In neoplastic cells of lung adenocarcinomas, TM is expressed but its correlation with growth potential has not been studied. As TM expression has a negative correlation with cell proliferation in lung squamous cell carcinomas, we examined its growth effect on lung adenocarcinoma cells of the A549 cell line by inhibiting TM expression with antisense oligodeoxynucleotides (ODN). In the antisense ODN transfected cells, the expression of TM mRNA was decreased to 49% at 12 h and 47% at 24 h, which was in accordance with TM expression at the protein level. By IdU (5-iodo-2'-deoxyuridine) incorporation assay, the growth of A549 cells was found to have decreased to 36% of the control level at 24 h post-transfection. The suppression of cell growth was maintained in a concentration-dependent manner for 48 h after transfection, when the expression of TM started to rebound. In the transfected cells, the G1 phase cell count was reduced to 60.7%, compared with 68.2% in the control transfectants. These results suggest that TM expression may play a suppressive role in the proliferation activity of A549 lung adenocarcinoma cells.     

LAK细胞体外杀伤直肠腺癌细胞的扫描电镜观察

应用扫描电镜观察体外LAK细胞与直肠腺癌细胞相互作用时的形态学变化。结果表明:LAK细胞与HR8348细胞均具有主动互相趋向运动,效靶细胞借其细胞突起及微绒毛相互接触。LAK细胞及肿瘤细胞的细胞突起及微绒毛由早期的平面接触逐渐发展为犬牙交错状结合。效靶细胞紧密结合后,靶细胞鼓泡,细胞膜出现环形穿孔。互相接触,结合的微绒毛及细胞突起在靶细胞的溶解过程中起到一个物理微桥的作用。LAK细胞分泌的杀伤物质通过微桥介导靶细胞的溶解。效靶细胞互相结合的微绒毛间形成关闭小室,它可能与维持局部杀伤物质浓度有关。     

Phase II evaluation of esorubicin (4′ deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study

Summary Esorubicin (4 deoxydoxorubicin) is a new analogue of the anthracycline, doxorubicin. This compound lacks the hydroxyl group at 4 position on the amino sugar of the anthracycline. Phase II study was designed to determine the clinical response rate and to define the qualitative and quantitative toxicities of esorubicin in patients with adenocarcinoma of the pancreas. Fifty-eight patients with inoperable adenocarcinoma of the pancreas were entered on the study, 47 were evaluable for response, and 57 were evaluable for toxicity. The dose of esorubicin was 30 mg/m² for good risk patients and 25 mg/m² for poor risk patients every 21 days and administered IV push through a side arm of a running IV. Diphenhydramine, 50 mg is administered IM prior to the administration of the drug to block local venous reaction. Subsequent doses of esorubicin were modified according to granulocyte and platelet nadirs and the drug was not administered until recovery of platelets (> 100,000/ul) and wbc (> 3000/ul). Three partial responses, 20 stable, and 31 with increased disease were observed. Forty-seven had severe granulocytopenia (< 250), and two patients had severe thrombocytopenia (< 25,000). One patient experienced a decrease in left ventricular ejection fraction with a total dose of 180 mg/m². The dose of esorubicin in this study demonstrated that the drug has minimal activity in adenocarcinoma of the pancreas but the toxicity is tolerable. Search should continue for single agents with activity in this disease.     

血管内皮细胞生长因子在大肠癌中的表达

目的 :探讨血管内皮细胞生长因子在大肠癌中的表达规律。方法 :应用VEGF抗体 ,采用免疫组化S -P法 ,对 6 2例大肠癌组织和 6 2例正常大肠上皮进行染色。结果 :大肠癌组织中VEGF的表达明显高于正常对照组 (P <0 .0 5 ) ,伴有淋巴结转移或远处转移的大肠癌组织中VEGF的表达明显高于其相应无转移组 (分别为P <0 .0 5和P <0 .0 1) ,DukesC期大肠癌中VEGF的表达亦明显高于DukesA、B期大肠癌 (P <0 .0 5 )。结论 :大肠癌组织中有VEGF的高水平表达 ,VEGF与大肠癌的生长、转移有关     

平消胶囊配合化学药物治疗晚期肺腺癌的临床观察

本文应用平消胶囊配合化学药物治疗52例晚期肺腺癌。全组CR2例,PR25例,总有效率为51.9%,且73.0%的患者症状改善,75.0%的患者功能状态得到改善,1年生存率为36.5%。结果表明平消胶囊与化学药物并用可以提高晚期肺腺癌的治疗效果,改善患者的生存质量。平消胶囊是治疗晚期肺腺癌的有效中成药之一。     

胰腺癌 P16、 P53及 PCNA 的表达及其临床意义

目的：研究胰腺癌中 Ｐ１６和 Ｐ５３基因产物的表达及其临床意义。方法：应用免疫组化 Ｌ Ｓ Ａ Ｂ法研究２８例胰腺癌组织中 Ｐ１６蛋白和 Ｐ５３蛋白的表达情况,并进行增殖细胞核抗原（ Ｐ Ｃ Ｎ Ａ）检测,计算细胞增殖指数（ Ｐｒｏｌｉｆｅｒａｔｉｏｎ ｉｎｄｅｘ, Ｐ Ｉ）。结果： Ｐ１６蛋白低表达和 Ｐ５３蛋白过表达均有促进胰腺癌细胞增殖的作用。 Ｐ１６蛋白表达与淋巴结转移无关; Ｐ５３蛋白高表达者具有较高的淋巴结转移率,预后较差。 Ｐ１６蛋白低表达与 Ｐ５３蛋白高表达共存者,其恶性度最高,预后最差。结论：联合检测 Ｐ１６和 Ｐ５３蛋白表达情况,更能充分反映胰腺癌的生物学行为,对胰腺癌患者预后判断及临床治疗有指导意义。     

Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma

We conducted a phase II evaluation of fazarabine 1.75–2.0 mg/m²hr over 72 hours every 28 days in 14 previously untreated patients with advanced adenocarcinoma of the pancreas. The intial dose was 1.75 mg/m²/hr in 10 patients, and 2.0 mg/m²hr in 4 patients. The dose was escalated in 8 patients, including all 4 who started at the higher dose level. Toxicity was unexpectedly mild. The median WBC nadir was 4.4 (range: 2.4–15.8)×10³/l, the median absolute neutrophil nadir was 3.2 (range: 0.9–13.0)×10³/l, and the median platelet count was 134.0 (range: 48.0–291.0)×10³/l. Gastrointestinal toxicity was generally mild. No major responses were seen, excluding, with 95% confidence, a response rate in excess of 20%.